Summit Trail Advisors LLC Has $248,000 Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Summit Trail Advisors LLC lessened its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 11.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 754 shares of the medical instruments supplier’s stock after selling 98 shares during the quarter. Summit Trail Advisors LLC’s holdings in West Pharmaceutical Services were worth $248,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the company. Pitcairn Co. grew its holdings in shares of West Pharmaceutical Services by 3.4% during the 1st quarter. Pitcairn Co. now owns 875 shares of the medical instruments supplier’s stock worth $346,000 after purchasing an additional 29 shares in the last quarter. Copperwynd Financial LLC grew its holdings in shares of West Pharmaceutical Services by 4.0% during the 4th quarter. Copperwynd Financial LLC now owns 778 shares of the medical instruments supplier’s stock worth $274,000 after purchasing an additional 30 shares in the last quarter. Clearbridge Investments LLC lifted its position in shares of West Pharmaceutical Services by 0.7% during the 1st quarter. Clearbridge Investments LLC now owns 4,495 shares of the medical instruments supplier’s stock worth $1,779,000 after buying an additional 31 shares during the period. RFG Advisory LLC lifted its position in shares of West Pharmaceutical Services by 2.3% during the 1st quarter. RFG Advisory LLC now owns 1,465 shares of the medical instruments supplier’s stock worth $580,000 after buying an additional 33 shares during the period. Finally, Ballentine Partners LLC lifted its position in shares of West Pharmaceutical Services by 4.7% during the 2nd quarter. Ballentine Partners LLC now owns 742 shares of the medical instruments supplier’s stock worth $244,000 after buying an additional 33 shares during the period. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Price Performance

West Pharmaceutical Services stock opened at $309.85 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.34 and a quick ratio of 1.68. The company has a market capitalization of $22.57 billion, a PE ratio of 40.88, a price-to-earnings-growth ratio of 10.58 and a beta of 1.01. West Pharmaceutical Services, Inc. has a one year low of $265.00 and a one year high of $413.70. The business has a 50 day simple moving average of $302.72 and a 200 day simple moving average of $336.46.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.22). The company had revenue of $702.10 million for the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. West Pharmaceutical Services’s quarterly revenue was down 6.9% compared to the same quarter last year. During the same quarter last year, the business earned $2.11 EPS. On average, sell-side analysts forecast that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current fiscal year.

Insider Buying and Selling

In related news, VP Charles Witherspoon sold 1,029 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the completion of the transaction, the vice president now owns 1,478 shares in the company, valued at approximately $443,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.53% of the stock is owned by corporate insiders.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.